Gå direkt till huvudinnehållet

Androgen alopeci (manligt håravfall)

Senast uppdaterad: Senast reviderad:
Sakkunnig:
Definition:
En progressiv, icke-ärrbildande form av håravfall hos män.
Förekomst:
Mycket vanligt tillstånd i högre åldrar.
Anamnes:
Gradvis debut, långsam progression. Inga andra symtom/besvär. Ofta positiv familjeanamnes.
Kliniska fynd:
Typisk fördelning av tunnare hår/hårlösa områden. 
Diagnostik:
Diagnosen baseras på anamnes och kliniska fynd.
Behandling:
Finasterid och minoxidil används mest. Andra terapier, såsom laser, kan rekommenderas.
  1. Nationellt kliniskt kunskapsstöd. Håravfall. Medicinskt godkänd 2016-05-01 (Hämtad 2020-06-01). nationelltklinisktkunskapsstod.se  
  2. Phillips TG, Slomiany WP, Allison R. Hair Loss: Common Causes and Treatment. Am Fam Physician. 2017;96(6):371‐378. PMID:28925637. PubMed  
  3. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136‐141.e5. PMID:28396101. PubMed  
  4. Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9‐17. PMID:28349362. PubMed  
  5. Kische H, Arnold A, Gross S. Sex Hormones and Hair Loss in Men From the General Population of Northeastern Germany. JAMA Dermatol. Published online April 12, 2017. doi:10.1001/jamadermatol.2017.0297 DOI  
  6. Mirmirani P. Age-related hair changes in men: mechanisms and management of alopecia and graying. Maturitas. 2015 Jan;80(1):58-62.
  7. Gupta M, Mysore V. Classifications of Patterned Hair Loss: A Review. J Cutan Aesthet Surg. 2016;9(1):3‐12. PMID:27081243. PubMed  
  8. Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial published online ahead of print, 2021 Oct 11. J Eur Acad Dermatol Venereol. 2021;10.1111/jdv.17738. PMID: 34634163 PubMed  
  9. Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. Dermatolog Treat. 2014 Apr;25(2):156-61. doi: 10.3109/09546634.2013.813011. DOI  
  10. Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. DOI  
  11. Katzer T, Leite Junior A, Beck R, da Silva C. Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. Dermatol Ther. 2019;32(5):e13059. PMID:31400254. PubMed  
  12. Arca E, Acikgøz G, Tastan HB et al. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209: 117-25. PubMed  
  13. Kiguradze T, Temps WH, Yarnold PR, et al. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. PMID:28289563. PubMed  
  14. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019 Aug 9;13:2777-2786. PMID: 31496654 PubMed  
  15. Rousso DE, Kim SW. A review of medical and surgical treatment options for androgenetic alopecia. JAMA Facial Plast Surg 2014; Nov-Dec;16(6): 444-50. pmid:25188680 PubMed  
  16. Afifi L, Maranda EL, Zarei M, et al. Low-level laser therapy as a treatment for androgenetic alopecia. Lasers Surg Med. 2017;49(1):27‐39. PMID:27114071. PubMed  
  • Remy Waardenburg, specialist i allmänmedicin, medicinsk redaktör Medibas

Tidigare sakkunniga

  • Lena Wanger, med dr och hudspecialist, Stockholm